AIMS: To report treatment and outcome in patients with malignant and benign pheochromocytoma and abdominal paraganglioma. METHODS: Review of clinical and therapeutic features in 85 patients with pheochromocytoma or abdominal paraganglioma between 1976 and 1999. RESULTS: Thirty-nine of 85 patients presented with symptoms other than classical paroxysmal attacks. Paragangliomas were more often malignant (7/15) than pheochromocytomas (7/70). No recurrences have occurred in 71 patients with tumours initially classified as benign after a median follow-up time of 144 months (range 7-287). Nine of 14 patients with tumours classified as malignant have developed metastasis and/or local recurrence. Treatment of malignant tumours with cyclophosphamide, vincristine and dacarbazine (CVD) improved or stabilised the disease in three of four patients. CONCLUSION: Life long follow-up of patients with benign pheochromocytoma is not necessary. Combination chemotherapy (CVD) is a valid option in the treatment of malignant pheochromocytomas and abdominal paragangliomas.
AIMS: To report treatment and outcome in patients with malignant and benign pheochromocytoma and abdominal paraganglioma. METHODS: Review of clinical and therapeutic features in 85 patients with pheochromocytoma or abdominal paraganglioma between 1976 and 1999. RESULTS: Thirty-nine of 85 patients presented with symptoms other than classical paroxysmal attacks. Paragangliomas were more often malignant (7/15) than pheochromocytomas (7/70). No recurrences have occurred in 71 patients with tumours initially classified as benign after a median follow-up time of 144 months (range 7-287). Nine of 14 patients with tumours classified as malignant have developed metastasis and/or local recurrence. Treatment of malignant tumours with cyclophosphamide, vincristine and dacarbazine (CVD) improved or stabilised the disease in three of four patients. CONCLUSION: Life long follow-up of patients with benign pheochromocytoma is not necessary. Combination chemotherapy (CVD) is a valid option in the treatment of malignant pheochromocytomas and abdominal paragangliomas.
Authors: R Tofighi; B Joseph; S Xia; Z-Q D Xu; B Hamberger; T Hökfelt; S Ceccatelli Journal: Proc Natl Acad Sci U S A Date: 2008-02-12 Impact factor: 11.205
Authors: Graeme Eisenhofer; Jacques W M Lenders; Gabriele Siegert; Stefan R Bornstein; Peter Friberg; Dragana Milosevic; Massimo Mannelli; W Marston Linehan; Karen Adams; Henri J Timmers; Karel Pacak Journal: Eur J Cancer Date: 2011-10-28 Impact factor: 9.162